Two recently identified and tested gene-expression signatures may guide clinicians in selecting which patients may show a response to palbocicib, according to findings presented at the IMPAKT Breast Cancer Conference held 7–9 May 2015 in Brussels, Belgium.
Click here to read the article in full.
Source: ESMO
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.